ET190L1-Artemis™ Cell Therapy Results in Durable Disease Remissions with No Cytokine Release Syndrome or Neurotoxicity in Patients with Relapsed and Refractory B-Cell Lymphoma

被引：1
|
作者：
Ying, Zhitao [1 ]
Long, Li [2 ]
Liu, Hong [3 ]
Song, Yuqin [1 ]
Rizzieri, David A. [4 ,5 ]
Nejadnik, Bijan [6 ]
Zhu, Jun [1 ]
Liu, Cheng [3 ]
机构：
[1] Peking Univ, Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Dept Lymphoma,Minist Educ, Beijing, Peoples R China
[2] Eureka Therapeut Inc, Lafayette, CA USA
[3] Eureka Therapeut Inc, Emeryville, CA USA
[4] Duke Univ, Med Ctr, Dept Med, Div Hematol Malignancies & Cellular Therapy, Durham, NC 27710 USA
[5] Duke Univ, Sch Med, Div Hematol Malignancies & Cellular Therapy, Durham, NC USA
[6] Eureka Therapeut Inc, Clin Dev, Emeryville, CA USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-113163
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1689
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Modified R-DAOx as salvage therapy in patients with relapsed or refractory diffuse large B-cell lymphoma
    Rigacci, L.
    Fabbri, A.
    Mappa, S.
    Nassi, L.
    Lenoci, M.
    Puccini, B.
    Alterini, R.
    Chitarrelli, I
    Carrai, V
    Lauria, F.
    Bosi, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 61 - 61
  • [32] Modified R-DHAOx as salvage therapy in patients with relapsed or refractory diffuse large B-cell lymphoma
    Fabbri, A.
    Rigacci, L.
    Lenoci, M.
    Mappa, S.
    Puccini, B.
    Nassi, L.
    Chitarrelli, I.
    Gozzetti, A.
    Alterini, R.
    Carrai, V.
    Bosi, A.
    Lauria, F.
    ANNALS OF ONCOLOGY, 2008, 19 : 219 - 220
  • [33] The Impact of Bridging Therapy Prior to CAR-T Cell Therapy on Clinical Outcomes of Patients with Relapsed Refractory Large B-Cell Lymphoma
    Lutfi, Forat
    Kansagra, Ankit
    Ali, Moaath Mustafa
    Bukhari, Ali
    Siglin, Jonathan
    Yan, Jingsheng
    Samanta, Santanu
    Holtzman, Noa G.
    Gottlieb, David
    Kim, Dong Won
    Lee, Seung-Tae
    Kocoglu, Mehmet Hakan
    Yared, Jean A.
    Hardy, Nancy M.
    Molitoris, Jason
    Mohindra, Pranshu
    Rapoport, Aaron P.
    Dahiya, Saurabh
    BLOOD, 2020, 136
  • [34] Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: Results from a Phase 1b Study
    Palomba, M. Lia
    Till, Brian G.
    Park, Steven I.
    Morschhauser, Franck
    Cartron, Guillaume
    Marks, Reinhard
    Shivhare, Mahesh
    Hong, Wan-Jen
    Raval, Aparna
    Chang, Alice C.
    Penuel, Elicia
    Popplewell, Leslie L.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (07): : E443 - E451
  • [35] Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma
    Epperla, Narendranath
    Lucero, Melanie
    Bailey, Tom
    Mirams, Laura
    Cheung, Jolenta
    Amet, Mona
    Milligan, Gary
    Chen, Lei
    BLOOD CANCER JOURNAL, 2024, 14 (01):
  • [36] Chimeric Antigen Receptor T-Cell Therapy in Elderly Patients with Relapsed or Refractory Large B-Cell Lymphoma: A Multicenter Study
    Tun, Aung M.
    Patel, Romil
    St-Pierre, Frederique
    Ouchveridze, Evguenia
    Niu, Alex
    Obasi, Jennifer
    Rosenthal, Allison C.
    Pophali, Priyanka A.
    Fenske, Timothy S.
    Karmali, Reem
    Ahmed, Sairah
    Johnston, Patrick B.
    BLOOD, 2023, 142
  • [37] Bridging Radiotherapy for Patients with Limited (<5 Disease Sites) Relapsed/Refractory B-Cell Non -Hodgkin Lymphoma Prior to CAR T-Cell Therapy
    Saifi, O.
    Breen, W.
    Lester, S. C.
    Rule, W. G.
    Stish, B. J.
    Rosenthal, A.
    Munoz, J.
    Lin, Y.
    Johnston, P.
    Ansell, S. M.
    Paludo, J.
    Khurana, A.
    Bisneto, J. Villasboas
    Wang, Y.
    Iqbal, M.
    Moustafa, M. Alhaj
    Murthy, H. S.
    Kharfan-Dabaja, M.
    Hoppe, B. S.
    Peterson, J. L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : S64 - S65
  • [38] CAR T-cell therapy for a relapsed/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome
    Chen, Liting
    Xu, Bin
    Long, Xiaolu
    Gu, Jia
    Lou, Yaoyao
    Wang, Di
    Cao, Yang
    Wang, Na
    Li, Chunrui
    Wang, Gaoxiang
    Wang, Ying
    Zhu, Li
    Wang, Jin
    An, Haiyun
    Xiao, Min
    Xiao, Yi
    Zhou, Jianfeng
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [39] Final results of a phase II trial of R-IDEA as salvage therapy in patients with relapsed/refractory diffuse large B-cell lymphoma
    Kondo, E.
    Yamamoto, K.
    Masunari, T.
    Takizawa, J.
    Miura, K.
    Masaki, Y.
    Matsumura, T.
    Hiramatsu, Y.
    Murakam, J.
    Tsujimura, H.
    Tomita, N.
    Maeda, Y.
    Kanno, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [40] Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma
    Hamadani, Mehdi
    Radford, John
    Carlo-Stella, Carmelo
    Caimi, Paolo F.
    Reid, Erin
    O'Connor, Owen A.
    Feingold, Jay M.
    Ardeshna, Kirit M.
    Townsend, William
    Solh, Melhem
    Heffner, Leonard T.
    Ungar, David
    Wang, Luqiang
    Boni, Joseph
    Havenith, Karin
    Qin, Yajuan
    Kahl, Brad S.
    BLOOD, 2021, 137 (19) : 2634 - 2645
12345